Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose levels and body weight reduction. Despite its therapeutic benefits, the use of Ozempic may cause side effects that affect patients' quality of life and their ability to continue treatment. This article aims to comprehensively analyze side effects associated with using Ozempic to provide a detailed understanding of their development mechanisms and their impact on patient's daily functioning.Material and Methods of Research: The literature was collected through searches in the PubMed and Google Scholar databases and references from the initially retrieved articles. Results: The literature review indicates various potential side effects of liraglutide, including gastrointestinal upset, pancreatitis, and the 'Ozempic face' phenomenon. This phenomenon, characterized by a skeletal facial appearance with deepened wrinkles, may result from the drug's impact on body composition and fat distribution, leading to a loss of subcutaneous fat in the face and a more pronounced appearance of underlying facial structures.Conclusion: Clinical studies highlight the need for continuous patient monitoring by healthcare providers to ensure the safe and effective use of Ozempic. Further education on a healthy lifestyle, diet, and physical activity is necessary to maintain the effects of drug therapy and prevent weight gain after treatment. Additional research on the long-term safety of GLP-1 is also crucial. Physicians should be aware of the potential risks and side effects associated with the use of Ozempic and should educate their patients to enable them to make informed decisions about their treatment.
Background: Acute cholecystitis and acute appendicitis are among the most common conditions leading to surgical admissions. However, their concurrent presentation is rare and poses significant diagnostic and therapeutic challenges. Compared with traditional open surgery, laparoscopy has revolutionized the management of various abdominal pathologies by providing enhanced visualization, shorter hospital stays, and faster recovery times. Case Presentation: A 66-year-old woman with severe right upper quadrant and lateral abdominal pain, and nausea was admitted to the general surgical ward. Physical examination showed tenderness and muscle guarding in the right upper quadrant, and a positive Murphy's sign. Laboratory investigations revealed leukocytosis, elevated inflammatory markers, and abnormal liver function. An inconclusive ultrasound led to a CT scan, diagnosing acute cholecystitis and acute appendicitis. A decision was made to perform simultaneous laparoscopic cholecystectomy and appendectomy. The patient had an uneventful recovery and was discharged after ten days with standard surgical recommendations. Conclusion: This case report highlights the importance of considering multiple potential causes of abdominal pain, especially with inconclusive initial imaging. Simultaneous laparoscopic cholecystectomy and appendectomy demonstrated in this case proved to be feasible, safe, and effective. Early and accurate diagnosis, facilitated by thorough clinical examination and advanced imaging, is crucial for prompt treatment. Surgeons must be prepared for rare concurrent presentations and capable of performing synchronous laparoscopic surgeries to improve patient outcomes and streamline recovery.
Nordic Walking (NW) is a widely practiced sport that was originally intended as a way for cross-country skiers to get a year-round workout. However, it quickly proved to be easy, enjoyable and undemanding, which led populations around the world to train NW. Today, the sport is used as rehabilitation in most medical specialties, as it is considered to be safe, not creating barriers, inexpensive and has no side effects. This article presents a literature review on the effects of NW on patients' mental and physical health.
Diabetes mellitus (DM) significantly increases the risk of erectile dysfunction (ED), affecting up to 52% of diabetic males. This review examines the epidemiology, pathophysiology, and treatment modalities of ED in diabetic patients. Key factors influencing ED in this population include poor glycemic control, obesity, hypertension, and the duration of diabetes. Both the latest reports on treatment and well-known articles containing fundamental knowledge about this condition were analyzed, mainly using online databases like PubMed. Effective management of ED in diabetic patients requires optimal glycemic control and lifestyle modifications such as diet, exercise, and weight management. Pharmacological treatments involve phosphodiesterase type 5 (PDE5) inhibitors like sildenafil, tadalafil, and vardenafil, which enhance erectile function by increasing cGMP levels. Alternatives for those unresponsive to oral medications include intracavernous injections, intraurethral alprostadil, vacuum constriction devices, low-intensity extracorporeal shock wave therapy (Li-ESWT), and penile prosthesis implantation. Emerging therapies like mesenchymal stem cell therapy and novel drug combinations offer promising avenues, focusing on cellular regeneration and improved vascular function. Despite the availability of these treatments, ED remains underreported due to patient embarrassment and healthcare provider hesitation, underscoring the need for increased awareness and proactive management. As projections indicate a rising global prevalence of ED, integrating ED management into comprehensive diabetes care is essential to enhance patient quality of life and address this significant public health issue.
Hyperlipidemia is becoming more and more severe condition among modern society. High-fat diet, sedentary lifestyle, lack of physical activity are the common factors leading to overweight, obesity and problems with serum lipid control. Dyslipidemia is one of the most important agents contributing to cardiovascular diseases snd therefore lower quality of life, disability and preamature death. This forces to constatnt searching for lipid-lowering drugs, that can be successfully use in the patients suffering from poor lipid control. Bempedoic acid (ETC-1020) is one of the newest, first in the class medicine, firstly approved to use in the USA on 21st February 2020 in monotheraphy, and then on 26th February in combination with ezetimibe. It is a small synthetic prodrug molecule that is activated by acyl-CoA synthetase in the liver. Bempedoic acid inhibits competitively adenosine triphosphate citrate lyase (ACL) and as a result it stops the further production of cholesterol and fatty acids. Research shows the ability of ETC-1020 to decline of LDL-C cholesterol up to 24%. It is also responsible for total cholesterol, non-HDL-C, ApoB and hs-CRP reduction. Bempedoic acid is characterized by good pharmacokinetics and pharmacodynamics. ECT-1020 has also a good drug-to-drug interaction profile. Many clinical trials have reported efficacy and safety of use with minimal side effects. Because of its target point is located in the liver and kidney, it can be successfully use in patients with statin intolerance due to bypassing decline of muscle cholesterol biosyntheisis, that is the main cause of musculosketelar adverse effects.
Migraine is a chronic condition that manifests itself periodically. It is characterized by recurrent, severe, often hemiplegic, throbbing headaches accompanied by autonomic symptoms in the form of nausea, vomiting, hypersensitivity to noise and light. For many years, triptans have been the gold standard in the treatment of migraine, acting by constricting blood vessels and inhibiting the release of neuropeptides. However, their efficacy is not satisfactory for all patients, especially those with cardiovascular disease. In response to the need for effective and safe therapies, gepants, a new class of drugs that block the calcitonin gene-related peptide (CGRP) receptor, have emerged. Rimegepant, one of the newest representatives of gepant, has been approved for the treatment of migraine both in the acute attack phase and prophylactically. Clinical trials have shown its effectiveness in reducing the number of days with migraine and alleviating associated symptoms. Rimegepant also has a favorable safety profile, making it a promising therapeutic option for migraine patients. This article aims to discuss in detail rimegepant as a new treatment option for migraine, including its mechanism of action, efficacy, safety profile, clinical trial and outlines the benefits of introducing this drug into standard clinical practice.